Drug intelligence / Profile preview

Agalaksivac-Oil

Development stage: Unknown
Lead developer: Vetal Company
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Agalaksivac-Oil is an inactivated bacterial vaccine developed by Vetal Company for the prevention of Contagious Mycoplasma Syndrome (Agalaksia) in sheep and goats. The vaccine contains inactivated *Mycoplasma agalactiae* antigens formulated with an oil adjuvant to enhance the immune response. It stimulates active immunity against the pathogen, which is a primary cause of mastitis, arthritis, and keratoconjunctivitis in small ruminants. It is currently approved and marketed as a commercial veterinary product.

Brand names: Agalaksivac-OilAgalaksivac Oil

Beyond the preview

Go deeper on Agalaksivac-Oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agalaksivac-Oil.

Explore the full profile